Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

Summary

To determine the safety and efficacy (overall response rate) of pembrolizumab in patients with relapsed or refractory ENKTL, and EBV-DLBCL

Timeline

Start

2019-03-12

Primary completion

2020-08-19

Completion

2020-08-19

Outcome

Outcome not reported

Stopped (Enrollment): “poor accrual”

Drugs

Indications